NRx Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.81) Per Share, HC Wainwright Forecasts (NASDAQ:NRXP)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Stock analysts at HC Wainwright issued their Q2 2024 earnings per share (EPS) estimates for NRx Pharmaceuticals in a report released on Friday, August 2nd. HC Wainwright analyst V. Bernardino expects that the company will earn ($0.81) per share for the quarter. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($4.00) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q3 2024 earnings at ($0.81) EPS and Q4 2024 earnings at ($0.86) EPS.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter.

Separately, Ascendiant Capital Markets cut their price objective on shares of NRx Pharmaceuticals from $50.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, June 7th.

NRx Pharmaceuticals Trading Up 0.5 %

NRx Pharmaceuticals stock opened at $2.02 on Monday. The stock has a 50-day moving average price of $2.73 and a two-hundred day moving average price of $18.83. NRx Pharmaceuticals has a 12 month low of $1.90 and a 12 month high of $7.33. The company has a market capitalization of $21.62 million, a PE ratio of -0.64 and a beta of 1.26.

Institutional Investors Weigh In On NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. One Wealth Management Investment & Advisory Services LLC bought a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 140,402 shares of the company’s stock, valued at approximately $65,000. One Wealth Management Investment & Advisory Services LLC owned approximately 0.16% of NRx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.